Basel, Switzerland

Klaus Kucher

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Novartis Ag. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Klaus Kucher in the Field of Shift Work Disorder Treatment.

Introduction

Klaus Kucher is an innovative inventor based in Basel, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of shift work disorder. His work has led to the development of a unique therapeutic approach that addresses the challenges faced by individuals working non-traditional hours.

Latest Patents

Kucher holds a patent for the "Use of a H3R inverse agonist for the treatment of shift work disorder." This invention focuses on utilizing a specific inverse agonist to alleviate the symptoms associated with shift work disorder, providing a potential solution for many affected individuals. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Klaus Kucher is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development in pharmaceuticals.

Collaborations

Throughout his career, Kucher has worked alongside notable colleagues, including Donald Johns and Judit Sovago. These collaborations have enriched his research and have been instrumental in the success of his projects.

Conclusion

Klaus Kucher's innovative work in the treatment of shift work disorder exemplifies the impact of dedicated inventors in the medical field. His contributions continue to pave the way for advancements that can improve the quality of life for many individuals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…